TRIAL INFORMATION
Sponsor:ApexCardio Pharmaceuticals
Therapeutic Area:Cardiology
Phase:PHASE II
Indication:Atrial Fibrillation
Target Enrollment:60 patients
Est. Duration:24 months
SITE INFORMATION
Site:MedPoint Clinical Research - Nashville
Principal Investigator:Dr. Sarah Chen, MD, PhD
Total FTE Capacity:12
Available FTE:1.8
Active Trials:6
Completed Trials:18
Pool Analysis
FTE Analysis
Financial
Risk Assessment
Recommendation
Patient Pool Adequacy Analysis
Assessing whether the available patient pool can support target enrollment
TOTAL POOL
3,200
AVAILABLE
2,620
580 allocated
REQUIRED
60
ADEQUACY RATIO
43.7x
Pool Utilization
Current Allocation18.1%
If This Trial Accepted20.0%
Pool is Sufficient
Available pool is 43.7x the target enrollment, providing a comfortable buffer for recruitment.
Pool Adequacy Score100 / 100